When taking hormone therapy (ADT) each of us experiences different side effects and each of us experiences them differently. Anyone experiencing hot flashes, probably the most commonly reported side effect of ADT during hormone therapy (ADT) knows how difficult, embarrassing and uncomfortable they can become as you go through your life. Some men, who find [...]
Malecare not only is the world’s largest prostate cancer support and education organization it also is responsible for prostate cancer research which has been recognized and published by the world’s largest organization of oncologists, the American Society of Clinical Oncologists (ASCO). At the last ASCO GU Conference Malecare presented a poster and had published an [...]
Today, I have some good news to share with you. Malecare, along with many other prostate cancer advocacy groups have been hard at work attempting to persuade members of Congress to not only maintain the Department of Defense Prostate Cancer Research Program (DoD PCRP), but to increase its funding for the next fiscal year. I [...]
In a recently published commentary about the optimal type of multi-modal hormone therapy for Gleason grade 4 and 5 prostate cancer the author addressed the discordance between results of several randomized trials evaluating survival benefit of continuous androgen deprivation therapy in men with high-risk disease. The study found that after combining data from multiple trials, [...]
I recently returned home from the American Association of Cancer Researchers (AACR) annual meeting held in New Orleans, La. The meeting was, as usual fantastic, but this years conclusion was by far the best I have experienced. The meeting’s closing session was reserved for remarks about the cancer "moonshot" initiative from Vice President Joe Biden. [...]
According to researchers at Brigham and Women’s Hospital in Boston Ma., men with aggressive prostate cancer who have radiation therapy to treat the cancer have better overall survival rates when the therapy is given at a high volume treatment facility. Paul Nguyen, MD, a physician researcher in the department of Radiation Oncology at Brigham said, “Our paper shows that [...]
A retrospective study, using the SEER Date, a U.S. national database, analyzed data from men diagnosed with prostate cancer and found that salvage radical prostatectomy (SRP) improved the long-term survival in men whose cancer has returned after receiving radiation therapy. We know that approximately 30% of men who have radiation therapy as their primary therapy will have a recurrence [...]
There has been a lot of hype and confusion about what is the best contrast for prostate cancer PET/CT scans. The two newest contrasts; (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) and (11)C-choline both have their supporters and their detractors. To try and evaluate the efficacy differences between these two contrasts in men who have suffered a bio-chemical recurrence [...]
The phase III trials for both Xtandi and Zytiga were similar. Both trials investigated men who progressed or died against placebo. Only 14% of men taking Xtandi during the trial progressed or died compared to 40% of the men in the placebo group. In the phase III trial of Zytiga 28% of the men [...]
Researchers at the Duke Cancer Institute along with other cancer centers, in the largest analysis of its kind have found that the organ site where prostate cancer spreads has a direct impact on a man’s survival. They found that men with lymph-only metastasis statistically have the longest overall survival possibility, while those with liver involvement [...]
